Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,226 stopped studies mapped to Malignant Digestive System Neoplasm and descendants · 91% state a reason
Over the 2,226 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05311176 | A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in…(nextHERIZON) | Phase 2 | terminated | Apr 5, 2022 | Imugene Limited | Study was discontinued because of slow enrollment and organizational priorities and not because of… | Safety / toxicity |
| NCT02807181 | SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line…(SIRCCA) | Phase 2 / Phase 3 | terminated | Jun 21, 2016 | Sirtex Medical | Slow enrollment | Enrollment / accrual |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT04732286 | A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With… | Phase 3 | terminated | Feb 1, 2021 | Hoffmann-La Roche | The study was completed as pre-specified in the protocol. Study was terminated only for… | Other (stated, no rule matched) |
| NCT01834235 | QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat… | Phase 1 / Phase 2 | terminated | Apr 17, 2013 | Precision Biologics, Inc | DSMB terminated the trial for futility. | Efficacy / futility |
| NCT03949907 | Early IntraVenous Administration of Nutritional Support(IVANS) | N/A | terminated | May 14, 2019 | Fondazione IRCCS Policlinico San Matteo di Pavia | Changes in anticancer treatment protocols which limit recruitment | Enrollment / accrual |
| NCT05242822 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or… | Phase 1 | terminated | Feb 16, 2022 | Kinnate Biopharma | Due to a change in the Sponsor's corporate strategy the study was terminated early by the Sponsor… | Enrollment / accrual |
| NCT01550510 | Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for… | Phase 1 / Phase 2 | terminated | Mar 12, 2012 | Thomas Jefferson University | Closed: low enrollment, many treatment options available for Colorectal Cancer | Enrollment / accrual |
| NCT04203641 | L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer | Phase 1 / Phase 2 | terminated | Dec 18, 2019 | Helix BioPharma Corporation | The primary reason for early termination was budget constraint. | Funding |
| NCT04853043 | Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic…(APK Mutant) | Phase 2 | terminated | Apr 21, 2021 | University of Utah | PI Determination - Slow recruitment, funding concerns, poor response to treatment | Enrollment / accrual |
| NCT05251233 | Role of Proton Pump Inhibitors on the Postoperative Course Following… | Phase 2 | terminated | Feb 22, 2022 | Washington University School of Medicine | Investigator and study team chose to end study early. | Investigator |
| NCT01555489 | Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard… | Phase 2 | terminated | Mar 15, 2012 | Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT02414100 | Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With… | — | withdrawn | Apr 10, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | No subjects were enrolled. Study team was not able to grow cell lines for the tumors. | Enrollment / accrual |
| NCT05757492 | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients… | Phase 1 | terminated | Mar 7, 2023 | Coherus Oncology, Inc. | The study was terminated for strategic reasons (not for safety concerns) | Safety / toxicity |
| NCT03820544 | SEMS Placement Before Surgery in Unblocking Bile Duct in Patients With Periampullary… | N/A | terminated | Jan 29, 2019 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Interest in this study changed and it was decided to end enrollment early | Enrollment / accrual |
| NCT03374852 | CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced… | Phase 2 | withdrawn | Dec 15, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | PI Left institution on 8/6/2018 and study has been final reported with IRB. Never opened to accrual | Investigator |
| NCT02939807 | A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular… | Phase 2 | withdrawn | Oct 20, 2016 | Medical University of South Carolina | study is being rewritten for different disease population | Other (stated, no rule matched) |
| NCT05448677 | Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First…(ABE-LIVER) | Phase 2 | terminated | Jul 7, 2022 | University Hospital, Grenoble | Study terminated due to recruitement issues | Enrollment / accrual |
| NCT06194877 | A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With… | Phase 1 | terminated | Jan 8, 2024 | MapKure, LLC | Funding terminated due to business reasons | Funding |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or… | Phase 2 | terminated | Aug 1, 2018 | M.D. Anderson Cancer Center | Lack of Efficacy | Efficacy / futility |
| NCT02311712 | Non-endoscopic EC Screening Program in Northern Iran(NESP) | N/A | suspended | Dec 8, 2014 | Tehran University of Medical Sciences | Waiting to receive capsule sponge device from the manufacturer. | Drug supply |
| NCT06001372 | Ketamine-assisted Psychotherapy (KAP) for Patients With Existential Distress Associated…(TREK) | Early Phase 1 | terminated | Aug 21, 2023 | University of Utah | Challenges with feasibility | Other (stated, no rule matched) |
| NCT05565794 | Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements | Phase 2 | terminated | Oct 4, 2022 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | slow recruitment | Enrollment / accrual |
| NCT05940844 | Study of OB-002 in Patients With Refractory Metastatic Cancer | Phase 1 | withdrawn | Jul 11, 2023 | Orion Biotechnology Polska Sp. z o.o. | study terminated due to changes in the drug development plan | Other (stated, no rule matched) |
| NCT05737706 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | Phase 1 | terminated | Feb 21, 2023 | Mirati Therapeutics Inc. | Formulation challenges | Other (stated, no rule matched) |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid… | Phase 2 | terminated | May 12, 2020 | Elevation Oncology | Business decision | Sponsor / business decision |
| NCT04476537 | RNA Precision Oncology in Advanced Pancreatic Cancer(HIPPOCRATES) | N/A | terminated | Jul 20, 2020 | Columbia University | Lack of feasibility | Other (stated, no rule matched) |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT04450836 | Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic…(SOREGATT) | Phase 2 | terminated | Jun 30, 2020 | UNICANCER | Following the presentation of the SUNLIGHT study results at ASCO GI and the rapid change in patient… | Other (stated, no rule matched) |
| NCT04108481 | Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer(iRE-C) | Phase 1 | terminated | Sep 30, 2019 | University of Iowa | DSMC-directed closure | Other (stated, no rule matched) |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with… | Phase 1 | terminated | Sep 17, 2020 | IGM Biosciences, Inc. | Study terminated due strategic corporate pivot to focus on auto-immune indications | Sponsor / business decision |
| NCT05375708 | Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with…(SIRIUS) | Phase 2 | suspended | May 17, 2022 | UMC Utrecht | Pilot study findings pointed to a overhaul in study design | Other (stated, no rule matched) |
| NCT01372696 | Endoscopic Characteristics of Colonic Tumours(C-LST) | N/A | withdrawn | Jun 14, 2011 | Professor Michael Bourke | study abandoned | Other (stated, no rule matched) |
| NCT04952753 | Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy…(daNIS-3) | Phase 2 | terminated | Jul 7, 2021 | Novartis Pharmaceuticals | The study was terminated early due to the halt of NIS793 treatment and urgent safety measures… | Safety / toxicity |
| NCT05494866 | A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage…(IntenSify) | Phase 1 | terminated | Aug 10, 2022 | German Cancer Research Center | lack of efficacy paired with high toxicity | Safety / toxicity |
| NCT03636607 | Diagnostic Significance of Single Center, Open and Prospective Evaluation of… | N/A | withdrawn | Aug 17, 2018 | Fifth Affiliated Hospital, Sun Yat-Sen University | No participents enrolled | Enrollment / accrual |
| NCT03889093 | Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The… | N/A | terminated | Mar 26, 2019 | University of Minnesota | PI Left Institution | Investigator |
| NCT03520790 | Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer | Phase 1 | terminated | May 11, 2018 | Dana-Farber Cancer Institute | Phase II was not pursued due to futility based on the results of the NAPOLI-3 therapeutic clinical… | Efficacy / futility |
| NCT04866836 | A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of… | Phase 2 | terminated | Apr 30, 2021 | The First Affiliated Hospital with Nanjing Medical University | The study was prematurely terminated due to difficulties in recruitment. | Enrollment / accrual |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in… | — | withdrawn | May 17, 2021 | Pfizer | The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea. | Drug supply |
| NCT05179837 | Endoscopic Optical Coherence Tomography for Screening and Diagnosis of Colorectal… | N/A | terminated | Jan 5, 2022 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT04976660 | TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors | Phase 1 / Phase 2 | withdrawn | Jul 26, 2021 | Tarus Therapeutics, Inc. | Tarus is conducting clinical development under a single IND, specifically IND for TT-10 (PORT-6).… | Other (stated, no rule matched) |
| NCT06144827 | A Pilot Study For Patients Receiving Radiation Therapy for Liver Cancer(HepQuant) | N/A | withdrawn | Nov 22, 2023 | Montefiore Medical Center | PI indicated that the site was unable to procure shunt. No participants were enrolled and this… | Enrollment / accrual |
| NCT04316013 | Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial | Phase 3 | terminated | Mar 20, 2020 | Peter MacCallum Cancer Centre, Australia | Not meeting recruitment timelines | Enrollment / accrual |
| NCT04629339 | Study of INCB086550 in Select Solid Tumors | Phase 2 | terminated | Nov 16, 2020 | Incyte Corporation | Strategic business decision to terminate the study effective immediately. This is due to a company… | Sponsor / business decision |
| NCT05446129 | A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in… | Phase 1 | terminated | Jul 6, 2022 | Boehringer Ingelheim | Company decision | Sponsor / business decision |
| NCT05166577 | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With… | Phase 1 | terminated | Dec 22, 2021 | Viracta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT05584540 | UNTIRE: Cancer-related Fatigue With Digital Treatment | N/A | withdrawn | Oct 18, 2022 | Dana-Farber Cancer Institute | loss of funding | Funding |
| NCT05137899 | Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy(ADVANCE HCC) | Phase 2 | terminated | Nov 30, 2021 | Ontario Clinical Oncology Group (OCOG) | Recruitment challenges, Hoffman La Roche strategic priority shift | Enrollment / accrual |
| NCT05770882 | Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | terminated | Mar 16, 2023 | Great Novel Therapeutics Biotech & Medicals Corporation | The overall profile does not support development for Hepatocellular Carcinoma | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 11, 2025source: clinicaltrials